Treprostinil
Payments companies reported to CMS as associated with Treprostinil. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Treprostinil, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Treprostinil
These are the largest totals companies reported as associated with Treprostinil. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Murali Chakinala | Saint Louis, MO | Pulmonary Disease | $350.55 |
| Harold Palevsky | Philadelphia, PA | Critical Care Medicine (Internal Medicine) | $273.95 |
| Gustavo Heresi Davila | Cleveland, OH | Pulmonary Disease | $236.05 |
| Naomi Habib | Phoenix, AZ | Critical Care Medicine (Internal Medicine) | $226.00 |
| Jimmy Smith | Lexington, KY | Critical Care Medicine (Internal Medicine) | $216.75 |
| Nicholas Kolaitis | San Francisco, CA | Pulmonary Disease | $202.37 |
| Maanasi Samant | Chicago, IL | Pulmonary Disease | $196.13 |
| Roxana Sulica | New York, NY | Critical Care Medicine (Internal Medicine) | $187.79 |
| Rajan Saggar | Los Angeles, CA | Pulmonary Disease | $186.75 |
| Eric Roberts | Milwaukee, WI | Cardiovascular Disease | $185.73 |
Prescribed Treprostinil?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.